MedTrace Logo

Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer

NCT06203613 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-02-16

No results posted yet for this study

Summary

In this study, we will investigate the diagnostic efficacy and safety of \[18F\]F-H3RESCA-3A12 and \[68Ga\]Ga-NOTA-3A12 in metastatic gastric and pancreatic cancers, and evaluate the sensitivity and specificity of the use of \[18F\]F-H3RESCA-3A12 and \[68Ga\]Ga-NOTA-3A12 for diagnosing metastatic gastric and pancreatic cancers . This study will provide a new method for the noninvasive target-specific diagnosis of gastric and pancreatic cancer, and provide intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment.

Conditions

  • Positron Emission Tomography
  • Pancreatic Neoplasms
  • Igestive System Neoplasms

Interventions

RADIATION

[18F]F-H3RESCA-3A12及[68Ga]Ga-NOTA-3A12

The dose of \[18F\]RCCB6 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 MCi\]/kg, and the method of administration was intravenous push, with a single visualization administered once.

Sponsors & Collaborators

  • YiHui Guan

    lead OTHER

Principal Investigators

  • Fang Xie, PhD · Huashan Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-09-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06203613 on ClinicalTrials.gov